Yosemite Founder Reed Jobs Seeks to Revolutionize Biotech with AI

Reed Jobs, the founder of Yosemite, a venture firm focused on biotech innovation, is making waves in the industry with his ambitious plans to revolutionize drug discovery and clinical trial design using AI. As the son of Steve Jobs, Reed has a reputation for being easy to like, but he's not afraid to talk about his work and the impact he hopes to make.

Jobs' passion for biotech is evident in his discussion of Yosemite's portfolio companies, Azalea and Quarry. Azalea, born from a grant to Jennifer Doudna's lab, is now in the clinic, while Quarry is working on a novel therapeutic approach called induced proximity. Jobs is proud of the progress these companies have made, and he's eager to see them become serious players in the biotech space.

With a team of 17 members, Yosemite has come a long way since its inception in 2023. Jobs credits AI's impact on drug discovery and clinical trial design as a key driver of the firm's growth. By leveraging a mix of philanthropy and outside investment capital, Yosemite is able to drive innovation in the biotech space and create new opportunities for companies like Azalea and Quarry.

As Jobs looks to the future, he's driven by the expanding opportunity in biotech. He believes that the industry is growing faster than expected, and he's eager to be at the forefront of this trend. With Yosemite's ambitious plans and Reed Jobs' passion for innovation, it's clear that this venture firm is one to watch in the world of biotech.